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ess under CC BY-NC-Abstract The purpose of this study was to compare the pharmacokinetic proﬁles of tetramethylpyrazine
phosphate (TMPP) in plasma and extracellular ﬂuid of the cerebral cortex of rats via three delivery routes:
intranasal (i.n.), intragastric (i.g.) and intravenous (i.v.) administration. After i.n., i.g. and i.v. administration of a
single-dose at 10 mg/kg, cerebral cortex dialysates and plasma samples drawn from the carotid artery were
collected at timed intervals. The concentration of TMPP in the samples was analyzed by HPLC. The area under
the concentration–time curve (AUC) and the ratio of the AUCbrain to the AUCplasma (drug targeting efﬁciency,
DTE) was calculated to evaluate the brain targeting efﬁciency of the drug via these different routes of
administration. After i.n. administration, TMPP was rapidly absorbed to reach its peak plasma concentration
within 5 min and showed a delayed uptake into cerebral cortex (tmax¼15 min). The ratio of the AUCbrain dialysates
value between i.n. route and i.v. injection was 0.68, which was greater than that obtained after i.g. administration
(0.43). The systemic bioavailability obtained with i.n. administration was greater than that obtained by the i.g.
route (86.33% vs. 50.39%), whereas the DTE of the nasal route was 78.89%, close to that of oral administrationl Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
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Comparative pharmacokinetics of tetramethylpyrazine phosphate 75(85.69%). These results indicate that TMPP is rapidly absorbed from the nasal mucosa into the systemic
circulation, and then crosses the blood–brain barrier (BBB) to reach the cerebral cortex. Intranasal administration
of TMPP could be a promising alternative to intravenous and oral approaches.
& 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
2,3,5,6-Tetramethylpyrazine (ligustrazine, TMP) is a major biologically
active compound isolated from the Chinese herbal medicine Ligusticum
wallichii Franch. TMP possesses antiplatelet activities and has been
widely used in China for the treatment of patients with vascular
disorders such as myocardial and cerebral infarction1. It has been
reported that TMP may provide antithrombotic effects and neuropro-
tection against ischemic brain injury through suppression of inﬂamma-
tion, blocking of calcium channels, inhibiting the formation of free
radicals, and reducing the bioactivity of platelets2. It has also been
proposed to increase cerebral blood ﬂow during ischemic brain
infarction3.
The most widely used salt form of TMP in clinical therapy is TMP
phosphate (TMPP). However, the absorption of TMPP after oral
administration is variable and incomplete, with low bioavailability of
10%–30%4. Intravenous infusion every 4–6 h produces a superior
pharmacodynamic effect but brings poor patient compliance. There-
fore, an alternative route of administration is greatly needed.
In the recent years, systemic drug delivery through the nasal route
has received considerable attention5. Intranasal (i.n.) administration
offers some advantages including rapid absorption, avoidance of
hepatic ﬁrst-pass metabolism, and preferential drug delivery to brain
via the olfactory region6,7. Hence i.n. delivery could be especially
important in the management of crisis situations such as cerebral
infarction8. The nasal delivery of TMPP may provide a better
alternative to intragastric (i.g.) and intravenous (i.v.) administration.
Microdialysis is a continuous sampling technique to study
unbound drug disposition and metabolism in blood and tissues9.
Using this technique, TMP was reported to have appreciable blood–
brain barrier (BBB) penetrability after i.v. administration10. The
pharmacokinetics of TMP hydrochloride following i.n. and i.v.
administration also has been investigated using the brain micro-
dialysis technique in free-moving rats11. However, there is a
limitation associated with i.n. administration in awake rats: TMPP
administered nasally can be cleared from the nasal cavity into the
gastrointestinal tract. Therefore, to investigate the brain pharmaco-
kinetics of TMPP along with the plasma pharmacokinetics follow-
ing i.n., i.g. and i.v. administration in parallel, our research was
carried out using brain microdialysis in anaesthetized rats with a
tracheotomy. These studies tested the efﬁcacy of the nasal route of
delivery, and could indicate whether there exists a direct nose-to-
brain transport of TMPP. In addition, the brain pharmacokinetics of
TMPP following oral administration was investigated.2. Materials and methods
2.1. Chemicals, reagents and animals
Tetramethylpyrazine phosphate (TMPP) was purchased from Limin
Pharmaceutical Company (Guangdong, China). Carbamazepine (inter-
nal standard, I.S.) was supplied by Hengyi Pharmaceutical Co., Ltd.(Tianjin, China). Methanol (HPLC grade) was purchased from Hanbon
Sci. & Tech. Co., Ltd. (Jiangsu, China). Water was prepared in a Milli-
Q water puriﬁcation system (Millipore, Bedford, MA, USA). All other
chemicals and reagents used were of analytical grade.
The brain microdialysis system was obtained from BAS
bioanalytical systems, Inc. (Indiana, USA), and concentric micro-
dialysis probes (MD-2204, membrane length: 4 mm, cutoff:
30 kDa) were used in this study. The artiﬁcial cerebrospinal ﬂuid
(ACSF) buffer (147 mmol/L NaCl, 4 mmol/L KCl, 2.3 mmol/L
CaCl2) was prepared weekly, ﬁltered, degassed and used as the
perfusate12.
Male Sprague–Dawley rats weighing 200–250 g were obtained
from the Experimental Animal Center of Sun Yat-sen University,
and maintained on a light/dark cycle. Temperature and relative
humidity were maintained at 25 1C and 50%, respectively. All care
and handling of animals were approved by the Animal Ethics
Committee of Sun Yat-sen University. The rats were fasted
overnight (approximately 12 h) before each experiment.
2.2. Preparation of TMPP solution for administration
Dosing solution of 25 mg/mL was prepared by dissolving TMPP
powder in physiological saline for the i.n. and i.v. administration,
and dosing solution of 5 mg/mL was prepared by dissolving
TMPP powder in distilled water for i.g. route. The preparations
were made immediately prior to drug administration.
2.3. Animal experiment
2.3.1. Experiment design
Thirty-six Sprague–Dawley rats randomly divided into six groups
were used in this study (n¼6), three groups for plasma PK study
following i.n., i.g. or i.v. administration and the other three groups
for brain microdialysis analysis of the above three delivery routes.
TMPP solution was administered at a single dose of 10 mg/kg
body weight (BW) to each rat.
2.3.2. Blood sampling and treatment for PK studies
The rats were anesthetized with an intraperitoneal injection of
urethane (1.0 g/kg), after which tracheotomy and cannulation of
the carotid artery was performed. For i.v. injection, dosing
solutions were delivered using a 1 mL syringe into the femoral
vein (a cannula was inserted for injection). For i.n. delivery, the
esophagus and the passage of the nasopalatine duct were ﬁrst
occluded to prevent drug being cleared into the gastrointestinal
tract12. Then preparations were given via a cannula inserted 7 mm
into the left cavity. Oral gavage of TMPP was performed by
attaching a stainless steel feeding needle to a syringe containing
the oral formulation.
A volume of 0.25 mL of blood was collected pre-dose and at
time 0.033, 0.083, 0.25, 0.5, 1, 1.5, 2, 3 and 5 h post-dosing and
transferred into heparinized polystyrene tubes. Plasma was
Figure 1 Average TMPP concentration in plasma as a function of
time after intravenous, intranasal and oral administration of TMPP at a
dose of 10 mg/kg (mean7S.D., n¼6).
D. Meng et al.76separated by centrifugation at 10,000 rpm for 10 min and kept
frozen at 20 1C prior to analysis.
Plasma samples were processed with the following steps: a volume
of 100 μL plasma was pipetted into polystyrene tubes and 20 μL of I.
S. working solution (40 μg/mL) and 1 mL water were added. The
mixture was vortex mixed for 1 min and loaded onto a SPE cartridge
(60 mg/3 mL, Strata-X, Phenomenex, USA), which had been condi-
tioned by washing with methanol (1 mL) followed by water (1 mL).
The sample-loaded SPE cartridge was further washed with water
(1 mL) and TMPP ws eluted with 1 mL of methanol. A 20 μL aliquot
of this extract was subjected to HPLC separation.
2.3.3. Microdialysis procedure
Rats were anesthetized and mounted on a stereotaxic frame, the skull
was exposed and a small hole was drilled (þ2.0 mm lateral to the
midsagittal suture and 2.0 mm anterior to bregma). The dural and
arachnoid membranes were removed to avoid damage to the micro-
dialysis probes during their insertion into the brain. An intracerebral
guide cannula was implanted, secured by screw and cement.
A microdialysis probe was stereotaxically inserted via the guide
cannula into the cerebral cortex, identically to a depth of 4.0 mm
ventrally from the dura, according to the atlas of Paxinos and
Watson13.
To avoid the possible inﬂuence of tissue trauma resulting from
insertion of the probe on the microdialysis results, the probe was
perfused with ACSF at a ﬂow rate of 2 μL/min for 1 h to stabilize
solute levels around the dialysis membrane14. A 1 mL microsyringe
was ﬁtted to a precision pump (MD-1001) and connected to the tubing
to provide the perfusate solution. Outﬂow from probe (dialysate) was
connected to a refrigerated fraction collector (MD-1201). The rats were
then held in supine position, and tracheotomy, cannulation and other
procedures were completed before drug administration.
After the stabilization period, TMPP was administered at a
single dose of 10 mg/kg to each rat and dialysates were collected
every 10 min within 2 h and then every 20 min thereafter. 10 μL of
the brain dialysate was directly injected into HPLC system and
immediately analyzed after collection. Throughout the experiment,
the rats were placed on heating pads to maintain body temperature
at 36–37 1C. The position of the probe was veriﬁed by standard
histological procedures at the end of the experiment.
2.4. Analytical method
Plasma and dialysate concentrations of TMPP were measured by
an Agilent 1100 HPLC system equipped with a UV detector
(Agilent technologies, USA). Separations were carried out on an
Elipse XDB C18 column (150 mm 4.6 mm, 5 μm, Agilent,
USA) with a C18 guard column (Security Guard, Phenomenex,
USA). The mobile phase consisted of water-methanol (40:60, v/v)
at a ﬂow-rate of 0.7 mL/min and the detector wavelength was set
at 295 nm. The retention times of TMPP and I.S. were 3.6 min and
5.5 min, respectively. For plasma analysis, the lower limit of
quantiﬁcation (LLOQ) for TMPP was 20 ng/mL and the linear
range was 0.08–40.96 μg/mL in rat plasma. The LLOQ value of
the dialyste was 10 ng/mL and the method was linear over the
concentration range from 0.02 to 1.6 μg/mL.
With the premise that in vitro recoveries by gain and loss are
equal, in vivo extracellular drug concentration can be recalculated
with in vivo probe recovery by loss15. In the present study, in vitro
recoveries of TMPP by gain and loss evaluated at 2.0 μL/min ﬂow-
rate with four concentration levels (0.1, 0.2, 0.4 and 0.8 μg/mL) were30.472.6% and 45.173.0%, respectively, and were signiﬁcant
different (Po0.05). As the recoveries of the microdialysis probes
were constant, the concentrations of TMPP in dialysate measured
in vivo were analyzed in parallel and the data were not recalculated
with in vivo recovery to avoid deviation from actual data.
Before and at the end of the in vivo experiments, the in vitro
recovery by gain of TMPP for each probe was determined by
continuing the perfusion at the same settings in a calibration
solution. Change in the range of 5% was accepted.
2.5. Data analysis
Results obtained from the HPLC analyses were plotted as
concentration–time curves for plasma or brain dialysate. As the
in vitro recoveries were similar between probes, the concentration
of TMPP in cerebral cortex after different routes of administration
can be compared from the drug concentration in dialysate. PK
analysis was performed using the KINETICA 4.4 software.
The mean area under the curve (AUC) was calculated by the
trapezoidal method. The maximum concentration (Cmax) and
the time to reach peak concentration (tmax) were the observed
values. Results are presented as mean values7S.D.
The degree of TMPP targeting to brain after i.n. and i.g.
administration can be evaluated by the drug targeting efﬁciency
(DTE), The higher the DTE is, the further degree of TMPP
targeting to brain can be expected. DTE that represents the time








The mean plasma levels of TMPP following a single dose of i.n.,
i.g. and i.v. administration are shown in Fig. 1. The plasma drug
concentration data were best ﬁtted to a two-compartment open
model, and the PK parameters are presented in Table 1.
The plasma Cmax following i.n. administration was 2.8 times
Table 1 Plasma pharmacokinetic parameters of TMPP after intravenous, intranasal and oral administration at a dose of 10 mg/kg
(mean7S.D., n¼6).
Parameter i.n. i.g. i.v.
tmax (min) 5.00 11.6775.16 –
Cmax (μg/mL) 10.7072.67a 3.7971.05a 19.9272.21
t1/2α (min) 6.6071.80
a 13.6873.90a 3.1270.60
t1/2β (min) 41.1678.16 92.16722.56
a 33.8477.68
MRT (min) 54.02715.03 115.20734.22a 44.4179.03
AUC0 t (μg·min/mL) 530.437130.20 309.62784.01a 614.40796.61
Bioavailability (%) 86.33 50.39 –
aSigniﬁcantly different from i.v. group, Po0.05.
Figure 2 Average TMPP concentration in brain dialysate as a
function of time after intravenous, intranasal and oral administration
of TMPP at a dose of 10 mg/kg (mean7S.D., n¼6).
Comparative pharmacokinetics of tetramethylpyrazine phosphate 77higher compared to that after oral delivery and the nasal bioavail-
ability was 86.33%, 1.7 times higher than oral administration.
The unbound TMPP in the brain dialysate concentration–time
proﬁles following i.n., i.g. and i.v. application, respectively, are
presented in Fig. 2. Drug concentrations were plotted at the mid-
time point of each single collection interval. Similar to other
reports11, the TMPP concentration reached Cmax at 15 min after
i.n. and i.v. routes, faster than i.g. route (20.0075.48 min).
The brain dialysate drug concentration data were best ﬁtted to a
non-compartment open model, and selected PK parameters are
presented in Table 2. The ratio of the AUCbrain dialysates value
between i.n. route and i.v. injection was 0.68, which was greater
than that obtained after i.g. administration (0.43). The DTE of
nasal route was 78.89%, close to that of i.g. route (85.69%).4. Discussion
For the nasal administration groups the esophagus and the passage
of the nasopalatine duct were occluded under anesthesia to prevent
drug from being cleared into the gastrointestinal tract and
subsequently absorbed. There have been numerous pharmacoki-
netics studies using microdialysis sampling in anaesthetized
rats19–21, so we adopted a brain microdialysis technique in
anesthetic rats for our studies.
In this study, the brain dialysate was sampled by the micro-
dialysis method with time intervals of 10 min within 2 h and thenevery 20 min, thereafter enabling the calculation of AUC values
with sufﬁcient time points. The tubes connecting the pump, the
dialysis probe and the fraction collector were as short as possible
in order to reduce the effect of the void volume on sampling time.
There have been different opinions on the damage to the BBB
after insertion of a microdialysis probe. Recent publications
described a biphasic response in increased BBB permeability with
a prompt increase immediately after probe insertion, followed by a
second increase 1–2 days after insertion22. In this study the
animals were allowed to stabilize for 1 h after probe implantation,
and then each formulation was administered.
In a preliminary experiment we investigated the TMPP con-
centration in different parts of the rat brain using the homogenate
method, and there was no signiﬁcant difference between the
concentration TMPP in the olfactory, cerebellum and cerebral
cortex at 5 and 15 min. This was consistent with the conclusion of
the study by Liang et al.23, so we chose the cerebral cortex to
sample in the microdialysis experiment.
From the proﬁles in Figs. 1 and 2, comparison of i.n. and i.v.
delivery of TMPP demonstrated that i.n. administration of TMPP
achieved a much higher degree of drug delivery to brain tissue.
The ratio of the AUCbrain dialysates value between i.n. route and i.v.
injection was 0.68 and the bioavailability of i.n. administration
was 86.33%, while the DTE was 78.89%, indicating that TMPP
could be efﬁciently absorbed through the nasal mucosa into the
systemic circulation and then delivered to the brain in rats.
The mean residence time (MRT) calculation shows that the
decrease of TMPP in brain tissue was slower than that in the
plasma, which was the same as the results reported by Feng et al.11
The oral bioavailability of TMPP was lower than the nasal
bioavailability (50.39% vs. 86.33%). This suggests that nasal
absorption can circumvent the gastrointestinal tract, and may be
of practical value to avoid ﬁrst-pass effect frequently associated
with oral administration of TMPP.
The drug uptake into the brain from the nasal mucosa can occur
via three different pathways5. One is that drug may be absorbed into
the systemic circulation and subsequently reaches the brain by
crossing the BBB. The others are the olfactory pathway and the
trigeminal neural pathway by which the drug may permeate the brain
directly. The extent and the route of drug delivery to the brain mainly
depends on characteristics that include lipophilicity and molecular
weight (MW). For a small molecular weight lipophilic drug, the rate
of transport into the brain via the systemic pathway is rapid with the
tmax usually ranging from 1 to 20 min post-dosing
24,25. While small
molecular weight hydrophilic drugs can be delivered into the brain
via the olfactory pathway, with a tmax usually ranging from 30 to
60 min post-dosing and with relatively high brain bioavailability26.
Table 2 Selected pharmacokinetic measures of TMPP in brain dialysate after intravenous, intranasal and oral administration at a dose of
10 mg/kg (mean7S.D., n¼6).
Parameter i.n. i.g. i.v.
tmax (min) 15.00 20.0075.48 15.00
Cmax (μg/mL) 0.8670.23 0.2970.10a 1.0670.15
MRT (min) 82.60719.51 110.42730.30 101.93724.02
AUC0 t (μg·min/mL) 45.1277.34a 28.6176.28a 66.2576.69
DTE (%) 78.89 85.69 —
aSigniﬁcantly different from i.v. group, Po0.05.
D. Meng et al.78Hydrophilic drugs do not easily pass the BBB from the systemic
circulation after i.v. administration.
After nasal administration, TMPP reached a Cmax at 15 min in brain,
the DTE to the brain was 78.89%, and there was a time delay between
tmax in plasma and brain. Considering the physicochemical character-
ization of TMPP with a MW of 252.2 and a log P¼0.294 according to
our preliminary experiment, it is probable that TMPP was mainly
delivered from the nasal cavity into the systemic circulation and then
taken up via the BBB into the brain. The potential of nasal transport
can be increased with the use of absorption enhancers and more
effective formulations, and a controlled release nasal formulation is
under development in our lab. Intranasal administration of TMPP may
be a promising alternative to traditional routes.
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